Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study)
Aim. To analyse factors hampering the achievement of compensation of carbohydrate metabolism in patients with type 2 diabetes mellitus treated for3 months with diabeton MB at a daily dose of 90-120 mg under real practical conditions. Materials and methods. This open study included 70 patients w...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2010-12-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://dia-endojournals.ru/dia/article/viewFile/6058/3817 |
id |
doaj-6518a7cf4b174f3bac0972ff6d4a4961 |
---|---|
record_format |
Article |
spelling |
doaj-6518a7cf4b174f3bac0972ff6d4a49612021-06-02T21:37:31ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782010-12-01134545610.14341/2072-0351-60586016Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study)Irina Evgen'evna Sapozhnikova0Elena Nikolaevna Anufrieva1Ekaterina Iosifovna Tarlovskaya2Alexander Anatol'evich Sobolev3Kirov State Medical Academy, KirovKirov State Medical Academy, KirovKirov State Medical Academy, KirovKirov State Medical Academy, KirovAim. To analyse factors hampering the achievement of compensation of carbohydrate metabolism in patients with type 2 diabetes mellitus treated for3 months with diabeton MB at a daily dose of 90-120 mg under real practical conditions. Materials and methods. This open study included 70 patients with type 2 diabetes mellitus given gliclazide MB-based hypoglycemic therapy(90-120 mg/day); their HbA1c level was measured before and 3 months after the onset of therapy. Results. The treatment resulted in a significant decrease of the HbA1c level especially pronounced in patients capable of following the rational therapeuticstrategy. At the closing visit, each patient was prescribed a pathogenetically sound regime of combined hypoglycemic therapy. Conclusion. Poor efficacy of hypoglycemic treatment in real clinical practice is attributable to frequent prescription of monotherapy, untimely onsetof insulin administration, its correction and intensification to meet changing requirementshttps://dia-endojournals.ru/dia/article/viewFile/6058/3817type 2 diabetes mellitushypoglycemic therapygliclazide mbhba1c level |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Irina Evgen'evna Sapozhnikova Elena Nikolaevna Anufrieva Ekaterina Iosifovna Tarlovskaya Alexander Anatol'evich Sobolev |
spellingShingle |
Irina Evgen'evna Sapozhnikova Elena Nikolaevna Anufrieva Ekaterina Iosifovna Tarlovskaya Alexander Anatol'evich Sobolev Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study) Сахарный диабет type 2 diabetes mellitus hypoglycemic therapy gliclazide mb hba1c level |
author_facet |
Irina Evgen'evna Sapozhnikova Elena Nikolaevna Anufrieva Ekaterina Iosifovna Tarlovskaya Alexander Anatol'evich Sobolev |
author_sort |
Irina Evgen'evna Sapozhnikova |
title |
Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study) |
title_short |
Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study) |
title_full |
Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study) |
title_fullStr |
Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study) |
title_full_unstemmed |
Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study) |
title_sort |
barriers for efficacious hypoglycemic therapy in clinical practice (results of the dialogue study) |
publisher |
Endocrinology Research Centre |
series |
Сахарный диабет |
issn |
2072-0351 2072-0378 |
publishDate |
2010-12-01 |
description |
Aim.
To analyse factors hampering the achievement of compensation of carbohydrate metabolism in patients with type 2 diabetes mellitus treated for3 months with diabeton MB at a daily dose of 90-120 mg under real practical conditions.
Materials and methods.
This open study included 70 patients with type 2 diabetes mellitus given gliclazide MB-based hypoglycemic therapy(90-120 mg/day); their HbA1c level was measured before and 3 months after the onset of therapy.
Results.
The treatment resulted in a significant decrease of the HbA1c level especially pronounced in patients capable of following the rational therapeuticstrategy. At the closing visit, each patient was prescribed a pathogenetically sound regime of combined hypoglycemic therapy.
Conclusion.
Poor efficacy of hypoglycemic treatment in real clinical practice is attributable to frequent prescription of monotherapy, untimely onsetof insulin administration, its correction and intensification to meet changing requirements |
topic |
type 2 diabetes mellitus hypoglycemic therapy gliclazide mb hba1c level |
url |
https://dia-endojournals.ru/dia/article/viewFile/6058/3817 |
work_keys_str_mv |
AT irinaevgenevnasapozhnikova barriersforefficacioushypoglycemictherapyinclinicalpracticeresultsofthedialoguestudy AT elenanikolaevnaanufrieva barriersforefficacioushypoglycemictherapyinclinicalpracticeresultsofthedialoguestudy AT ekaterinaiosifovnatarlovskaya barriersforefficacioushypoglycemictherapyinclinicalpracticeresultsofthedialoguestudy AT alexanderanatolevichsobolev barriersforefficacioushypoglycemictherapyinclinicalpracticeresultsofthedialoguestudy |
_version_ |
1721400458529996800 |